ImmunityBio Addresses FDA Correspondence and Reaffirms Commitment to Advertising ComplianceBusiness Wire • 04/06/26
IBRX INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that ImmunityBio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitGlobeNewsWire • 04/06/26
IBRX SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026PRNewsWire • 04/04/26
INVESTOR NOTICE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action LawsuitPRNewsWire • 04/04/26
IBRX INVESTOR ALERT: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens BermanPRNewsWire • 04/04/26
ImmunityBio, Inc. (IBRX) Class Action Lawsuit: Investors Face May 26, 2026, DeadlinePRNewsWire • 04/03/26
ImmunityBio, Inc. (IBRX) Faces Securities Class Action Amid FDA Warning Regarding Unsupported Cancer Treatment Claims, $2 Billion Market Capitalization Wiped Out -- Hagens BermanGlobeNewsWire • 04/02/26
Deadline Approaching: ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. SmithBusiness Wire • 04/02/26
IBRX INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that ImmunityBio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitGlobeNewsWire • 04/02/26
ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens BermanPRNewsWire • 04/01/26
Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm Encourages ImmunityBio, Inc. (IBRX) Shareholders To Inquire About Securities Fraud Class ActionBusiness Wire • 04/01/26
ImmunityBio, Inc. (IBRX) Investors: May 26, 2026, Deadline in Securities Fraud Class Action Lawsuit – Contact Kessler Topaz Meltzer & Check, LLPBusiness Wire • 04/01/26
INVESTOR ALERT: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action LawsuitPRNewsWire • 03/31/26
Law Offices of Frank R. Cruz Encourages ImmunityBio, Inc. (IBRX) Shareholders To Inquire About Securities Fraud Class ActionBusiness Wire • 03/31/26
Law Offices of Howard G. Smith Encourages ImmunityBio, Inc. (IBRX) Shareholders To Inquire About Securities Fraud Class ActionBusiness Wire • 03/31/26
ImmunityBio Strengthens Balance Sheet with $100 Million of Financing Transactions Including $75 Million of Non-Dilutive Financing to Support Global Expansion and Advancement of Broader Immunotherapy PipelineBusiness Wire • 03/31/26
ROSEN, A TOP RANKED LAW FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRXNewsfile Corp • 03/31/26
IMMUNITYBIO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against ImmunityBio, Inc. and Encourages Investors to Contact the FirmGlobeNewsWire • 03/30/26
ImmunityBio ALERT: $IBRX Investors Who Lost Money Should Contact Block & Leviton By May 26th To Potentially Recover LossesNewsfile Corp • 03/30/26
Securities Fraud Investigation Into ImmunityBio, Inc. (IBRX) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law FirmBusiness Wire • 03/30/26
IBRX Class Action Reminder: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the ImmunityBio, Inc. Securities Fraud Class ActionGlobeNewsWire • 03/30/26
ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud InvestigationBusiness Wire • 03/30/26
INVESTOR NOTICE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - RGRD LawGlobeNewsWire • 03/30/26
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRXNewsfile Corp • 03/29/26